1. Clinical & Scientific Overview
Griseofulvin (TIP-MED-000347, Reference Code [8.34]-C77) is classified under
Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [8.34] (Terbinafine Hydrochloride & Griseofulvin). Representative Indian Market Examples (Edition 2.7 Ch 08 [8.34], p. 109): Terbinafine: Sebifin (Sun), Tyza (Abbott), Terbicip (Cipla), Zimig. Griseofulvin: Grisovin FP (GSK), Walavin FP (Wallace), Dermonorm — Strengths & Dosage Forms: Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
3. Mechanism of Action & Pharmacodynamics
Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022) for Terbinafine: First-line fungicidal oral therapy for dermatophytosis (tinea corporis, tinea cruris, tinea pedis) and toenail/fingernail onychomycosis. Griseofulvin: Paediatric Tinea capitis (scalp ringworm).
4. Therapeutic Indications & Evidence-Supported Uses
- Terbinafine: First-line fungicidal oral therapy for dermatophytosis (tinea corporis, tinea cruris, tinea pedis) and toenail/fingernail onychomycosis
- Griseofulvin: Paediatric Tinea capitis (scalp ringworm)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Terbinafine (Adults): 250 mg PO Once Daily (or 250 mg BD in recalcitrant dermatophytosis) for 2–4 weeks (Tinea corporis/cruris), 6 weeks (Fingernail), or 12 weeks (Toenail). Griseofulvin FP: Adults: 500–1000 mg PO OD/BD; Children (Tinea capitis): 15–20 mg/kg/day for 6–8 weeks
Administration & Meal Timing: Terbinafine may be taken with or without food; Griseofulvin MUST be taken WITH A HIGH-FAT MEAL or whole milk (doubles GI absorption!) | Once Daily (or BD per specialist protocol)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [8.34].
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
7. Contraindications, Precautions & High-Risk Warnings
- Terbinafine is CONTRAINDICATED in chronic or active liver disease and severe renal impairment (CrCl <50 mL/min!). Griseofulvin is CONTRAINDICATED in pregnancy (teratogenic; men must also avoid fathering a child during and for 6 months after Griseofulvin!), porphyria, hepatocellular failure, and SLE! Neither is effective against Candida or Pityriasis versicolor!
Key Clinical Precautions: Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
8. Adverse Effects Profile
- Terbinafine: Mild GI upset, headache, rash, reversible loss or distortion of taste (ageusia/dysgeusia). Griseofulvin: Headache, photosensitivity, GI upset
- Terbinafine: Idiosyncratic severe cholestatic/hepatocellular liver injury (after 2–6 weeks), SJS/TEN, agranulocytosis, subacute cutaneous lupus erythematosus. Griseofulvin: Lupus flare, Disulfiram-like alcohol reaction
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- TERBINAFINE IS A POTENT CYP2D6 INHIBITOR: Markedly increases plasma levels of Tricyclic Antidepressants (Amitriptyline, Nortriptyline), Beta-Blockers (Metoprolol, Carvedilol, Nebivolol -> bradycardia!), SSRIs, and Risperidone! Griseofulvin is a CYP450 INDUCER: Reduces efficacy of Warfarin (decreases INR!) and Oral Contraceptives (use barrier backup!)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [8.34].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Check liver tests (LFT) before starting a 4- to 12-week course of Sebifin/Tyza tablets; stop immediately if you develop persistent nausea, dark urine, yellow eyes, loss of taste, or skin rash; for Grisovin FP, take with milk/food and avoid sunlight and alcohol
- Meal & Clock Timing Instruction: Terbinafine may be taken with or without food; Griseofulvin MUST be taken WITH A HIGH-FAT MEAL or whole milk (doubles GI absorption!) (Once Daily (or BD per specialist protocol))
- Missed Dose Protocol: Take same day if remembered; do not double dose
- Geriatric Dispensing Pearl: In older adults with CrCl <50 mL/min or polypharmacy (Metoprolol/Amitriptyline), prefer topical Terbinafine/Luliconazole unless nail/extensive infection requires systemic therapy
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.33]-C76 Voriconazole — Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifu
- [8.13] Fluconazole — Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Ste
- [8.33] Itraconazole & Voriconazole — Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifu
- [8.34] Terbinafine Hydrochloride & Griseofulvin — Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inh